Epigenetic therapies - a new direction in clinical medicine
- PMID: 24845064
- DOI: 10.1111/ijcp.12436
Epigenetic therapies - a new direction in clinical medicine
Abstract
A major biomedical advance from recent years was the finding that gene expression and phenotypic traits may be shaped by potentially reversible and heritable modifications that occur without altering the sequence of the nucleotides, and became known as epigenetic changes. The term 'epigenetics' dates back to the 1940s, when it was first used in context of cellular differentiation decisions that are made during development. Since then, our understanding of epigenetic modifications that govern development and disease expanded considerably. The contribution of epigenetic changes to shaping phenotypes brings at least two major clinically relevant benefits. One of these, stemming from the reversibility of epigenetic changes, involves the possibility to therapeutically revert epigenetic marks to re-establish prior gene expression patterns. The strength and the potential of this strategy are illustrated by the first four epigenetic drugs that were approved in recent years and by the additional candidates that are at various stages in preclinical studies and clinical trials. The second particularity is the finding that epigenetic changes precede the appearance of histopathological modifications. This has the potential to facilitate the emergence of epigenetic biomarkers, some of which already entered the clinical arena, catalysing a major shift in prophylactic and therapeutic strategies, and promising to fill a decades-old gap in preventive medicine.
© 2014 John Wiley & Sons Ltd.
Similar articles
-
Cancer epigenetics: an introduction.Methods Mol Biol. 2015;1238:3-25. doi: 10.1007/978-1-4939-1804-1_1. Methods Mol Biol. 2015. PMID: 25421652 Review.
-
Epigenetic modification of nucleic acids: from basic studies to medical applications.Chem Soc Rev. 2017 May 22;46(10):2844-2872. doi: 10.1039/c6cs00599c. Chem Soc Rev. 2017. PMID: 28352906 Review.
-
Epigenomes as therapeutic targets.Pharmacol Ther. 2015 Jul;151:72-86. doi: 10.1016/j.pharmthera.2015.03.003. Epub 2015 Mar 20. Pharmacol Ther. 2015. PMID: 25797698 Review.
-
A new paradigm in toxicology and teratology: altering gene activity in the absence of DNA sequence variation.Reprod Toxicol. 2007 Jul;24(1):20-30. doi: 10.1016/j.reprotox.2007.05.002. Epub 2007 May 22. Reprod Toxicol. 2007. PMID: 17596910 Review.
-
[Epigenetics and cancer].Med Sci (Paris). 2005 Apr;21(4):405-11. doi: 10.1051/medsci/2005214405. Med Sci (Paris). 2005. PMID: 15811306 Review. French.
Cited by
-
Histone deacetylase inhibitors for leukemia treatment: current status and future directions.Eur J Med Res. 2024 Oct 26;29(1):514. doi: 10.1186/s40001-024-02108-8. Eur J Med Res. 2024. PMID: 39456044 Free PMC article. Review.
-
Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer.J Otolaryngol Head Neck Surg. 2016 Oct 28;45(1):54. doi: 10.1186/s40463-016-0168-9. J Otolaryngol Head Neck Surg. 2016. PMID: 27793210 Free PMC article.
-
Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes.Comput Struct Biotechnol J. 2015 May 7;13:358-65. doi: 10.1016/j.csbj.2015.04.007. eCollection 2015. Comput Struct Biotechnol J. 2015. PMID: 26082827 Free PMC article. Review.
-
Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets.J Otolaryngol Head Neck Surg. 2017 Jan 31;46(1):9. doi: 10.1186/s40463-017-0185-3. J Otolaryngol Head Neck Surg. 2017. PMID: 28143553 Free PMC article. Review.
-
Epigenetics, Media Coverage, and Parent Responsibilities in the Post-Genomic Era.Curr Genet Med Rep. 2016 Sep;4(3):92-97. doi: 10.1007/s40142-016-0092-3. Epub 2016 Jun 14. Curr Genet Med Rep. 2016. PMID: 27867757 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous